GENFIT Share Price Börse Stuttgart
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Börse Stuttgart
01:26:14 21/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 14.00 EUR | -2.10% |
|
+7.20% | +174.51% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 71Cr 82Cr 66Cr 60Cr 113.57Cr 7.88TCr 115.81Cr 780.97Cr 304.17Cr 3.96TCr 309.24Cr 302.48Cr 13TCr | P/E 2026 * |
36.4x | P/E 2027 * | 93.6x |
|---|---|---|---|---|---|
| Enterprise Value | 65Cr 76Cr 61Cr 56Cr 105.34Cr 7.31TCr 107.41Cr 724.37Cr 282.13Cr 3.67TCr 286.82Cr 280.56Cr 12TCr | EV / Sales 2026 * |
6.53x | EV / Sales 2027 * | 5.15x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -2.10% | ||
| 1 week | +7.20% | ||
| Current month | -4.11% | ||
| 1 month | +9.20% | ||
| 3 months | +66.27% | ||
| 6 months | +70.21% | ||
| Current year | +174.51% |
| 1 week | 12.94 |  | 14.74 |
| 1 month | 12.6 | | 15.4 |
| Current year | 5.06 | | 15.4 |
| 1 year | 3.58 | | 15.4 |
| 3 years | 3.3 | | 15.4 |
| 5 years | 2.96 | | 15.4 |
| 10 years | 2.96 | | 21.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.10% | +7.20% | - | - | 84Cr | |
| +1.14% | +3.46% | +4.57% | +24.14% | 5.05TCr | |
| -1.36% | +3.15% | +479.46% | +614.84% | 4.6TCr | |
| -2.04% | +2.82% | +18.13% | +91.23% | 4.28TCr | |
| +2.72% | +5.93% | +33.12% | +19.66% | 4.1TCr | |
| 0.00% | -3.91% | +17.87% | +47.98% | 3.2TCr | |
| +0.72% | +2.62% | +32.57% | +145.37% | 1.7TCr | |
| -1.85% | -0.25% | - | - | 1.71TCr | |
| +3.06% | +4.63% | +7.40% | +35.00% | 1.43TCr | |
| +0.50% | +2.49% | +83.90% | +46.53% | 1.38TCr | |
| Average | +0.08% | +2.01% | +84.63% | +128.09% | 3.05TCr | |
| Weighted average by Cap. | +0.18% | +2.37% | +104.14% | +152.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 12Cr 9.37Cr 8.58Cr 16Cr 1.12TCr 16Cr 110.94Cr 43Cr 562.24Cr 44Cr 43Cr 1.86TCr | 12Cr 14Cr 12Cr 11Cr 20Cr 1.39TCr 20Cr 137.35Cr 53Cr 696.08Cr 54Cr 53Cr 2.3TCr |
| Net income | 2.29Cr 2.67Cr 2.14Cr 1.96Cr 3.68Cr 255.71Cr 3.76Cr 25Cr 9.87Cr 128.38Cr 10Cr 9.81Cr 424.97Cr | 68L 79.43L 63.56L 58.26L 1.09Cr 76Cr 1.12Cr 7.53Cr 2.93Cr 38Cr 2.98Cr 2.92Cr 126.31Cr |
| Net Debt | -5.11Cr -5.97Cr -4.78Cr -4.38Cr -8.23Cr -571.35Cr -8.39Cr -57Cr -22Cr -286.84Cr -22Cr -22Cr -949.54Cr | -6.62Cr -7.73Cr -6.19Cr -5.67Cr -11Cr -739.63Cr -11Cr -73Cr -29Cr -371.33Cr -29Cr -28Cr -1.23TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | €14.00 | -2.10% | 7,373 |
| 19/26/19 | €14.30 | +4.69% | 10,242 |
| 18/26/18 | €13.66 | -1.44% | 2,077 |
| 17/26/17 | €13.86 | +7.11% | 11,667 |
| 14/26/14 | €12.94 | -2.56% | 7,281 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Select your edition
All financial news and data tailored to specific country editions
